Answers are grounded in this paper and cite their sources.
Medicaid covers nearly one-quarter of adults with mental illness in the United States [ 1 ], and antipsychotics have historically been a top drug class for Medicaid spending. In 2019, psychotherapeutic agents, which include antipsychotics and antidepressants, were the third most costly outpatient class for the program. Antipsychotic agents represented 9% of all Medicaid spending ($6.2 billion) and 10% of all Medicaid prescriptions (73.1 million claims) that year [ 2 ]. With the outsized role Medicaid plays in paying for behavioral health care and the growing number of beneficiaries in the program since the Affordable Care Act [ 3 ], it is important to monitor how and where resources are being devoted within the program.
No takes yet. Share an insight, caveat, or question.
Giron et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: